Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Lethaby, Anne ^a   Duckitt, Kirsten ^b   Farquhar, Cindy ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Campbell River and District General Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; ETAMSYLATE; FLURBIPROFEN; GESTAGEN; LEVONORGESTREL; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; TRANEXAMIC ACID;

ADVERSE EVENT; BLEEDING; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MENORRHAGIA; META ANALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; ADULT; DYSMENORRHEA; FEMALE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DYSMENORRHEA; FEMALE; HUMANS; MENORRHAGIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84874796240     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000400.pub3     Document Type: Review

References (60)

1. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstetricia et Gynecologica Scandinavica 1988;67:645-8.
2. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. American Journal of Obstetrics and Gynecology 1991;164:879-83.
3. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996;313:579-82.
4. Cameron IT. Dysfunctional uterine bleeding. Bailliere's Clinical Obstetrics and Gynaecology 1989;2:315-27.
5. Cameron IT, Leask R, Kelly RW, Baird DT. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987;34:99-110.
6. Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics & Gynecology 1990;76:85-8.
7. Smith SK, Haining RH, Reed-Thomas V, Cameron IT. The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology 1989:62.
8. Chamberlain G. Comparing treatments for menorrhagia. Nursing Times 1992;88:46.
9. Chamberlain G, Freeman R, Price F, Kennedy A, Green D, Eve L. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology 1991;98:707-11.
10. Chamberlain G, Freeman R, Price F, Kennedy A, Green D, Eve L. Raw data from RCT. Lorex Synthélabo Laboratory in UK.
11. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. British Journal of Obstetrics and Gynaecology 1989;96:840-4.
12. Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen J, Markham R. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstetrics & Gynaecology 1981;58(5):543-51.
13. Fraser IS, McCarron G. Randomised trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Australian & New Zealand Journal of Obstetrics & Gynaecology 1991;31(1):66-70.
14. Grover V, Usha R, Gupta U, Kalra S. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia-Oceania Journal of Obstetrics & Gynaecology 1990;16:255-9.
15. Hall P, MacLachlan N, Thorn N, Nudd MWE, Taylor CG, Garrioch DB. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. British Journal of Obstetrics and Gynaecology 1987;94:554-8.
16. Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandin and effects of ibuprofen. British Journal of Obstetrics and Gynaecology 1986;93:974-8.
17. Muggeridge J, Elder MG. Mefenamic acid in the treatment of menorrhagia. Research and Clinical Forums 1983;5:83-8.
18. Najam R, Agarwald D, Tyagi R, Singh S. Comparison of tranexamic acid with a combination of tranexamic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding. Journal of Clinical and Diagnostic Research 2010;4:3020-5.
19. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. British Journal of Obstetrics and Gynaecology 2005;112:1121-5.
20. Nygren KG, Rybo G. Prostaglandins and menorrhagia. Acta Obstetricia et Gynecologica Scandinavica Supplement 1983;113:101-3.
21. Rybo G, Nilsson S, Sikstrom B, Nygren KG. Naproxen in menorrhagia (letter). Lancet 1981;March:608-9.
22. Tsang BK, Domingo MT, Spence JEH, Garner PR, Dudley DK, Oxorn H. Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo. Canadian Journal of Physiology and Pharmacology 1987;65:2081-4.
23. van Eijkeren MA, Christiaens GCML, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. American Journal of Obstetrics and Gynecology 1992;166:1419-28.
24. Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstetrics & Gynaecology 1986;68:10-2.
25. Martinez Alcala FO, Casanova Alvarez N, Manzanilla Sevilla R, Gonzalez Iniguez R, Martinez Reyes y P. Efficacy and tolerability of mefenamic acid in dysfunctional uterine bleeding [Eficacia y tolerabilidad del acido mefenamico en la hipermenorrea disfuncional]. La Prensa Médica Mexicana 1979;44(11-12):295-8.
26. Vargyas JM, Campeau JD, Mishell DR. Treatment of menorrhagia with meclofenamate sodium. American Journal of Obstetrics & Gynecology 1987;157:944-50.
27. Jaisamrarn J, Sitavarin S, Suwikrom S, Kamolpornwijit W. Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics 2006;3:83.
28. Bland JM, Altman DG. Comparisons against baseline within randomised groups are often used and can be highly misleading. Trials 2011;12:264.
29. Chimbira TH, Anderson ABM, Turnbull AC. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. British Journal of Obstetrics and Gynaecology 1980;87:603-9.
30. Clarke A, Black N, Rowe P, Mott S, Howie K. Indications for and outcomes of total abdominal hysterectomy for benign disease: a prospective cohort study. British Journal of Obstetrics and Gynaecology 1995;102:611-20.
31. Cole S, Billewicz W, Thomson A. Sources of variation in menstrual blood loss. Journal of Obstetrics and Gynaecology of the British Commonwealth 1971;78(10):933-9.
32. Fraser IS, McCarron G, Markham R, Robinson M, Smyth E. Long term treatment of menorrhagia with mefenamic acid. Obstetrics & Gynaecology 1983;61:109-12.
33. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. American Journal of Obstetrics and Gynecology 1984;149:788-93.
34. Fraser IS, McCarron G, Markham R, Resta T. Blood and total fluid content of menstrual discharge. Obstetrics & Gynecology 1985;65:194-8.
35. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. Obstetrics & Gynecology 2001;98:806-14.
36. Fraser IS, Robert JP, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents. Part 2: In excessive or heavy menstrual bleeding. Drug Safety 2008;31(4):275-82.
37. Frick KD, Clark MA, Steinwachs DM, Langenberg P, Stovall D, Munro MG, et al.Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Women's Health Issues 2009;19(1):70-8.
38. Gath D, Cooper P, Day A. Hysterectomy and psychiatric disorder. Levels of psychiatric morbidity before and after hysterectomy. British Journal of Psychiatry 1982;140:335-40.
39. Hagenfeldt K. The role of prostaglandins and allied substances in uterine haemostasis. Contraception 1987;36(1):23-35.
40. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - a population study. Acta Obstetricia et Gynecologica Scandanavica 1966;45:320-51.
41. Haynes PJ, Hodgson H, Anderson AB, Turnbull AC. Measurement of menstrual blood loss in patients complaining of menorrhagia. British Journal of Obstetrics and Gynaecology 1977;84(10):763-8.
42. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
43. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
44. Higham JM, O'Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology 1990;97:734-39.
45. Kadir RA, Lukes AS, Kouides PA, Fernandez H, Goudemand J. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertility and Sterility 2005;84(5):1352-9.
46. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment and healthcare costs and utilisation in abnormal uterine bleeding. Value in Health 2007;10(8):183-94.
47. Lopez BA, Buckley S, Rees CM, Marshall JM. Meclofenamate inhibits prostaglandin E binding and adenylyl cyclase activation in human endometrium. Journal of Endocrinology 1991;129(3):439-45.
48. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynaecology and Obstetrics 2011;113(1):3-13.
49. Newton J, Barnard G, Collins W. A rapi method for measuring menstrual blood loss using automatic extraction. Contraception 1977;16:269-82.
50. National Institute for Health and Clinical Excellence (NICE). Heavy menstrual bleeding, 2007. http://guidance.nice.org.uk/CG44/. (accessed 21 November 2012).
51. Osei J, Critchley H. Menorrhagia, mechanisms and targeted therapies. Current Opinion in Obstetrics and Gynecology 2005;17(4):411-8.
52. Protheroe J. Modern management of menorrhagia. Journal of Family Planning and Reproductive Health Care 2004;30(2):118-22.
53. Rees MCP, DiMarzo V, Tippins JR, Morris HR, Turnbull AC. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. Journal of Endocrinology 1987;113:291-5.
54. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
55. Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Safety 2004;27(2):75-90.
56. Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology 1981;88:434-42.
57. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. British Journal of Obstetrics and Gynecology 2001;108(1):74-86.
58. Warner PE, Critchley HOD, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow up data. American Journal of Obstetrics and Gynecology 2004;190:1216-23.
59. Warner PE, Critchley HOD, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia II: is the 80-mL blood loss criterion useful in the management of complaint of menorrhagia?. American Journal of Obstetrics and Gynecology 2004;190:1224-9.
60. Willman EA, Collins WD, Clayton SC. Studies on the involvement of prostaglandins in uterine symptomatology and pathology. British Journal of Obstetrics and Gynaecology 1976;83:337-41.